FULC - CIK 0001680581
Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $0.00 | -100.0% |
| FY 2024 | $80.00M | +2752.0% |
| FY 2023 | $2.81M | -55.8% |
| FY 2022 | $6.34M | -66.9% |
| FY 2021 | $19.16M | +117.2% |
| FY 2020 | $8.82M | - |
Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Fulcrum Therapeutics, Inc.'s revenue declined from $8.82M to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.